Valuation and Targets, page-322

Referring back to a post in November:
When i raised the pharmacist issue with PAR people they replied in part
" Additionally, across our clinical trials, we have procedures in place for obtaining detailed feedback on patient experiences and adverse events. The information we receive is carefully evaluated by our medical and safety physicians and if indicated, may result in changes to management and monitoring to better improve patient experiences.

If you are aware of specific patient information, that individual is encouraged to meet with the physician who treated him/her to ensure event reporting is completed. "
The inference i drew was that they didn't know about the incident, maybe because it was indicated as "did not proceed".
Perhaps you or the attending physician should make a point of providing more detail?
Simon White is the investor relations manager, and could pass on any further feedback.
[email protected]